Estrella Immunopharma(ESLA)
$0.34+0.01 (+2.41%)
ESLA
Estrella Immunopharma stock drug pipeline
$0.34
At close:+0.01 (+2.41%)
Estrella Immunopharma (ESLA) Drug Pipeline
48 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Eb103 | Lymphoma, Non-Hodgkin, High-Grade B-Cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin's Lymphoma (Nhl), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Non-Hodgkin's, Adult, Hiv Associated Lymphoma, Cns Lymphoma | phase1AndPhase2 | Recruiting | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | Mar 14, 2024 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Eb103 | phase1AndPhase2 | Lymphoma, Non-Hodgkin, High-Grade B-Cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin's Lymphoma (Nhl), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Non-Hodgkin's, Adult, Hiv Associated Lymphoma, Cns Lymphoma | Recruiting | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | Mar 14, 2024 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Estrella Immunopharma, Inc. (ESLA) have in its pipeline
Estrella Immunopharma ESLA is currently developing the following drugs: Eb103. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

